Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021

Ilustraciones, mapas, gráficas

Autores:
Tipo de recurso:
Fecha de publicación:
2022
Institución:
Universidad de Caldas
Repositorio:
Repositorio Institucional U. Caldas
Idioma:
eng
spa
OAI Identifier:
oai:repositorio.ucaldas.edu.co:ucaldas/18111
Acceso en línea:
https://repositorio.ucaldas.edu.co/handle/ucaldas/18111
https://repositorio.ucaldas.edu.co/mydspace
Palabra clave:
Análisis clínicos
Diagnóstico
Niños
Infecciones por coronavirus
Enfermedades Autoinmunes
Niño
Pediatría
Rights
closedAccess
License
http://purl.org/coar/access_right/c_14cb
id REPOUCALDA_f786bc09e032969398885858956c5838
oai_identifier_str oai:repositorio.ucaldas.edu.co:ucaldas/18111
network_acronym_str REPOUCALDA
network_name_str Repositorio Institucional U. Caldas
repository_id_str
dc.title.none.fl_str_mv Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
title Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
spellingShingle Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
Análisis clínicos
Diagnóstico
Niños
Infecciones por coronavirus
Enfermedades Autoinmunes
Niño
Pediatría
title_short Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
title_full Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
title_fullStr Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
title_full_unstemmed Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
title_sort Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021
dc.contributor.none.fl_str_mv Sepúlveda Gallego, Luz Elena
dc.subject.none.fl_str_mv Análisis clínicos
Diagnóstico
Niños
Infecciones por coronavirus
Enfermedades Autoinmunes
Niño
Pediatría
topic Análisis clínicos
Diagnóstico
Niños
Infecciones por coronavirus
Enfermedades Autoinmunes
Niño
Pediatría
description Ilustraciones, mapas, gráficas
publishDate 2022
dc.date.none.fl_str_mv 2022-10-06T17:23:21Z
2022-10-06T17:23:21Z
2022-10-06
dc.type.none.fl_str_mv Trabajo de grado - Especialización
http://purl.org/coar/resource_type/c_7a1f
Text
info:eu-repo/semantics/bachelorThesis
https://purl.org/redcol/resource_type/TP
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.identifier.none.fl_str_mv https://repositorio.ucaldas.edu.co/handle/ucaldas/18111
Universidad de Caldas
Repositorio Universidad de Caldas
https://repositorio.ucaldas.edu.co/mydspace
url https://repositorio.ucaldas.edu.co/handle/ucaldas/18111
https://repositorio.ucaldas.edu.co/mydspace
identifier_str_mv Universidad de Caldas
Repositorio Universidad de Caldas
dc.language.none.fl_str_mv eng
spa
language eng
spa
dc.relation.none.fl_str_mv 1. Smatti M, Cyprian F, Nasrallah G, et al. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019 Aug 19;11(8):1-18
2. Richard-Eaglin A, Smallheer B. Immunosuppressive/Autoimmune Disorders. Nurs Clin North Am. 2018 Sep 1;53(3):319–34.
3. V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020;19(3):155–70.
4. Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clinical Immunology. 2020;217:1–2.
5. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20
6. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Current opinion in rheumatology. 2021;33(2):155–62
7. Gracia A, Martin E, Hernández G. New onset of autoimmune diseases following covid-19 diagnosis. Cells. 2021 Dec 1;10(12):1-19
8. Aggarwal A y Scott C. Global Issues in Pediatric Rheumatology. En Petty R, Laxer R, Lindsley C, et al. Textbook of Pediatric Rheumatology- ClinicalKey. 8th ed. Elsevier; 2020: 151-156
9. Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Jt Bone Spine. 2014 Mar 1;81(2):112–7
10. CREA (Centro de estudios de Enfermedades Autoinmunes) [Sitio web de https://www.urosario.edu.co/]. 29 de enero de 2018. Disponible en: https://www.urosario.edu.co/Periodico-NovaEtVetera/Nuestra-U/El-5-de-la-poblacion-enColombia-sufre-de-alguna/. Consultado septiembre 12 de 2021.
11. Palmezano J, Figueroa C, Rodríguez R, et al. Prevalencia y caracterización de las enfermedades autoinmunitarias en pacientes mayores de 13 años en un hospital de Colombia. Med interna México. 2018 J;34(4):522–35.
12. Londoño J, Peláez I, Cuervo F, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD - Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Rev Colomb Reumatol. 2018;25(4):245–56
13. Organización paramericana de la salud. Actualización Epidemiológica: Enfermedad por coronavirus (COVID-19) - [Sitio web de www.paho.org]. 21 de agosto de 2021. Disponible en: https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-porcoronavirus-covid-19-21-agosto-2021. Consultado en septiembre 11 de 2021].
14. Gobernación del Huila - Emergencia por COVID 19. [Página web de www.huila.gov.co]. 2021. Disponible en: https://www.huila.gov.co/salud/publicaciones/9522/gobernacion-delhuila---emergencia-por-covid-19/. Consultado en junio 5 de 2021.
15. Instituto nacional de salud. Modelos-covid-19 [Página web de www.ins.gov.co]. 2021 disponible en: https://www.ins.gov.co/Direcciones/ONS/modelos-covid-19. Consultado en septiembre 11 de 2021.
16. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):276–88
17. Iannarella R, Lattanzi C, Cannata G, et al. Coronavirus infections in children: From SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features. Acta Biomed. 2020;91(3):1–14.
18. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatric Infectious Disease Journal. 2020 May;39(5):355-368
19. Khera N, Santesmasses D, Kerepesi C, et al. COVID-19 mortality rate in children is Ushaped. Aging (Albany NY). 2021 Aug 8;13(16):54-62.
20. Piedra L, Howe M, Francis J, et al. Latinos and the Pandemic: Results from the National Social Life, Health, and Aging Project—COVID-19 Study. J Appl Gerontol. 2022 May 1;41(5):1465-1472.
21. Andrasfay T, Goldman N. Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations. medRxiv Prepr Serv Heal Sci. 2020 Oct 15; 118 (5): 1-22
22. Thomas S, Griffiths C, Smeeth L, et al. Burden of Mortality Associated With Autoimmune Diseases Among Females in the United Kingdom. Am J Public Health. 2010 Nov 1;100(11):2279-2287.
23. Mitratza M, Klijs B, Hak A, et al. Systemic autoimmune disease as a cause of death: mortality burden and comorbidities. Rheumatology (Oxford). 2021 Mar 1;60(3):1321–30
24. Kim H, Cho S, Kim J, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 2020 Jun 1;50(3):526–33.
25. Safiri S, Kolahi A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):1-10
26. Barber M, Clarke A. Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017 Sep 1;29(5):480–5
27. Kent T, Davidson A, Newman D, et al. Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey. Lupus. 2017 Sep 1;26(10):1095–100.
28. Jacobs P, Bissonnette R, Guenther L. Socioeconomic Burden of Immune-Mediated Inflammatory Diseases — Focusing on Work Productivity and Disability. J Rheumatol Suppl. 2011 Nov 1;88(88):55–61.
29. Jiang M, Near A, Desta B, et al. Original research: Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015. Lupus Sci Med. 2021 Sep 14;8(1):1-10
30. Strand V, Tundia N, Song Y, et al. Economic burden of patients with inadequate response to targeted immunomodulators for rheumatoid arthritis. J Manag Care Spec Pharm. 2018 Apr 1;24(4):344–52.
31. Fair D, Rodriguez M, Knight A, et al. Depression And Anxiety In Patients With Juvenile Idiopathic Arthritis: Current Insights And Impact On Quality Of Life, A Systematic Review. Open Access Rheumatol Res Rev. 2019;11:237-252.
32. Quilter M, Hiraki L, Korczak D. Depressive and anxiety symptom prevalence in childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2019 Jun 1;28(7):878–87
33. Geist R, Grdisa V, Otley A. Psychosocial issues in the child with chronic conditions. Best Pract Res Clin Gastroenterol. 2003 Apr 1;17(2):141–52.
34. Abdul-Sattar A, Magd S, Negm M. Associates of school impairment in Egyptian patients with juvenile idiopathic arthritis: Sharkia Governorate. Rheumatol Int. 2013 Sep 26;34(1):35– 42.
35. Sentenac M, Santos T, Augustine L, et al. Chronic health conditions and school experience in school-aged children in 19 European countries. Eur Child Adolesc Psychiatry. 2022; 40(2):1-11
36. Walsh S, Rau L. Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health. 2000;90(9):1463–6.
37. Souza D, Santo A, Sato E. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol. 2012;39(3):496–503.
38. Gacem O, Zeroual Z, Arrada Z, et al. Predictors of mortality in childhood-onset Systemic Lupus Erythematosus. Rheumatology. 2021 Nov 11;60(5):1–10.
39. Yen E, McCurdy D. Autoimmune Diseases: Declining Mortality Between 1999 and 2008 However Continuing to be a Leading Cause of Death in Children-A 10-Year Retrospective Review. American College of Rheumatology. 2012;1–31.
40. Jung S, Kim W. Targeted Immunotherapy for Autoimmune Disease. Immune Netw. 2022 Feb 1;22(1):1-23
41. Departamento nacional de planeación. Ficha de caracterización 2019 [Página web de sirhuila.gov.co]. 30 de diciembre de 2019. Disponible en: http://tempo.sirhuila.gov.co/category/dnp/fichas-de-caracterizacion-municipal/. Citado el 12 de septiembre de 2021.
42. Pollard C, Morran M, Kalinoski A. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52(11):549–57.
43. Domingues R, Lippi A, Setz C, et al. SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime. Aging (Albany NY). 2020 Sep 30;12(18):18778–89
44. Wang M, Zhao R, Gao L, et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020 Nov 25;10:1-17.
45. Kutsuna S. Clinical Manifestations of Coronavirus Disease 2019. JMA J. 2021 Apr 4;4(2):76-80.
46. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724.
47. Dotan A, Muller S, Kanduc D, et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021 Apr 1;20(4):1–10.
48. Chowdhury S, Oommen A. Epidemiology of COVID-19. J Dig Endosc. 2020;11(1):3-7
49. Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2021 Aug 31;1(9):1–9.
50. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–4.
51. Tang K, Hsu B, Chen D. Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review. Frontiers in Immunology. 2021;(12): 1-16
52. Taherifard E, Movahed H. Hematologic autoimmune disorders in the course of COVID19: a systematic review of reported cases. Hematology. 2021;26(1):225–39
53. Novelli L, Motta F, Santis M, et al. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmun. 2021;117(2021):1–24.
54. Rodríguez Y, Novelli L, Rojas M, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020 Nov 1;114:1–18
55. Li J, Liu H, Yin X, et al. COVID-19 illness and autoimmune diseases: recent insights. Inflamm Res. 2021;70(4):407–28.
56. López M, Peral M, Calabuig I, et al. Case series of acute arthritis during COVID-19 admission. Ann Rheum Dis. 2021;80(4):1–2.
57. Saricaoglu E, Hasanoglu I, Guner R. et al. The first reactive arthritis case associated with COVID‐19. J Med Virol. 2021;93(1):192–3.
58. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):1–3.
59. Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. 2020;383(3):1–2
60. Uppal N, Kello N, Shah H. et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int reports. 2020;5(11):1–5.
61. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020 Jun 3;369:1–7.
62. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1–8.
63. Feldstein L, Rose E, Horwitz S, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. 2020;383(4):1–13
64. Debliquis A, Harzallah I, Mootien J, et al. Haemophagocytosis in bone marrow aspirates in patients with COVID‐19. Br J Haematol. 2020;190(2):1–4.
65. Wood H, Jones J, Hui K, et al. Secondary HLH is uncommon in severe COVID-19. Br J Haematol. 2020;190(5):1–3.
66. M Verheyden, M Grosber, J Gutermuth. Et al. Relapsing symmetric livedo reticularis in a patient with COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(11):684–6.
67. Dominguez M, Diaz B, Garcia P, et al. Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19). J Eur Acad Dermatol Venereol. 2020;34(10):536–7.
68. Restivo D, Centonze D, Alesina A, et al. Myasthenia Gravis Associated With SARSCoV-2 Infection. Ann Intern Med. 2020;173(12):1–2.
69. Foresti C, Servalli M, Frigeni B, et al. COVID-19 provoking Guillain-Barré syndrome: The Bergamo case series. Eur J Neurol. 2021 Oct;28(10):84-85.
70. Mubarak M, Tolouian R, Kowalewska J, et al. Comment: Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis. 2020 jul 1;14(4):323–5
71. Slimani Y, Abbassi R, Zohra F. Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. J Med Virol. 2021;93(2):1184–7.
72. Cardoso E, Hundal J, Feterman D, et al. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020;39(9):2811–5.
73. Mehan W, Yoon B, Lang M. Paraspinal Myositis in Patients with COVID-19 Infection. AJNR Am J Neuroradiol. 2020 oct 1;41(10):1949–52.
74. Riphagen S, Gomez X, Gonzalez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8.
75. Saavedra C. Consenso Colombiano SARS-CoV-2/COVID-19. Infectio. 2021;25(4):153– 67
76. Gobernación del Huila. Datos de primera infancia, infancia y adolescencia [Página web de huila.gov.co]. 12 de junio de 2020. Disponible en: 61 www.huila.gov.co/mujer/publicaciones/9578/datos-de-primera-infancia-infancia-yadolescencia/. Consultado en agosto 26 de 2021
77. Departamento Administrativo Nacional de Estadística (DANE). Censo nacional de población y vivienda 2018 [Página web de dane.gov.co]. 30 de agosto de 2019. Disponible en: https://sitios.dane.gov.co/cnpv/#!/est_pob. Consultado en: septiembre 8 de 2021
78. Instituto Nacional de Salud Colombia - Boletines casos COVID-19 Colombia [Página web de ins.gov.co]. 2021 disponible en: https://www.ins.gov.co/Paginas/Boletines-casosCOVID-19-Colombia.aspx. Consultado en: septiembre 28 de 2021
79. Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J Rheumatol. 1996 Nov; 23(11):1968–74.
80. Rosenberg A. Longitudinal analysis of a pediatric rheumatology clinic population. J Rheumatol. 2005 Oct; 32(10):1992–2001.
81. Terrell D, Beebe L, Vesely S, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010 Mar; 85(3):174–80
82. Kamphuis S, Silverman E. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010 Sep; 6(9):538–46.
83. Angum F, Khan T, Kaler J, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May;12(5):1-7.
84. Sohn E. Why autoimmunity is most common in women. Nature. 2021 Jul 1;595(7867):51–3.
85. Kühne T, Buchanan G, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003; 143(5):605–8.
86. Instituto Nacional de Salud. El Coronavirus en Colombia [Página web de coronaviruscolombia.gov.co] 2022. Disponible en: https://coronaviruscolombia.gov.co/Covid19/index.html. Consultado el 30 de mayo de 2022.
87. Wu Z, McGoogan J. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–42.
88. Stokes E, Zambrano L, Anderson K, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. Morb Mortal Wkly Rep. 2020; 69(24): 759-765.
89. American Academy of Pediatrics. Children and COVID-19: State-Level Data Report [Página web de www.aap.org]. 2022. Disponible en: https://www.aap.org/en/pages/2019- novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Consultado en: 30 de mayo de 2022.
90. Dawood F, Porucznik C, Veguilla V, et al. Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. JAMA Pediatr. 2022 Jan 1; 176(1): 59–67.
91. Dong Y, Mo X, Hu Y. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China - PMC. J Emerg Med. 2020 Apr;58(4):712–3.
92. Murillo E, Aguilar F, Delgado I, et al. Predictors of laboratory-positive COVID-19 in children and teenagers. Public Health. 2020 Dec 1; 189 (2020):153-157.
93. Wurzel D, McMinn A, Hoq M, et al. Original research: Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study. BMJ Open. 2021 Nov 8; 11(11):1-9
94. Pathak E, Salemi J, Sobers N, et al. COVID-19 in Children in the United States: Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020. J Public Heal Manag Pract. 2020 Apr 4; 26(4): 325–33
95. Williams P, Howard A, Hsu P, et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020 Dec 1; 52(7):801.
96. Chu V, Schwartz N, Donnelly M, et al. Comparison of Home Antigen Testing With RTPCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Intern Med. 2022 Apr 29; e221827: 1-9
97. Lindsay L, Secrest M, Rizzo S, et al. Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA. BMJ Open. 2021; 11:e051707: 1-13
98. Lau C, Johns J, Merlene S, et al. Trends in COVID-19 Testing and Positivity Rates from a Mobile Testing Program in the Phoenix Metropolitan Area. J Community Health. 2021 Dec 1;46(6):1221–5.
99. Naimoli A. Modelling the persistence of Covid-19 positivity rate in Italy. Socioecon Plann Sci. 2022 Jan 7;101225: 1-15
100. Furuse Y, Ko Y, Ninomiya K, et al. Relationship of test positivity rates with covid‐19 epidemic dynamics. Int J Environ Res Public Health. 2021 Apr 27;18(9):1-10
101. AlDallal A, AlDallal U, Al Dallal J. Positivity rate: an indicator for the spread of COVID19. Curr Med Res Opin. 2021;37(12):2067–76
102. Lindsley C. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 1987;30(7):838–9.
103. Feldman B, Birdi N, Boone J, et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996;129(4):513–8.
104. Wong K, Farooq Alam Shah M, Khurshid M, et al. COVID-19 associated vasculitis: A systematic review of case reports and case series. Ann Med Surg. 2022 Feb 1;74:103249:1- 5
105. Esposito S, Principi N. Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Paediatr Drugs. 2021;23(2):119-129.
106. Talarico R, Stagnaro C, Ferro F, et al. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol. 2020;2(9):e518–9.
107. Vacchi C, Meschiari M, Milic J, et al. COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. Rheumatology (Oxford). 2020;59(12):E147–50.
108. Bonometti R, Sacchi M, Stobbione P, et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24(18):9695–7
109. Bennett J, Brown C, Rouse M, et al. Immune Thrombocytopenia Purpura Secondary to COVID-19. Cureus. 2020 Jul; 12(7):1-5
110. Hindilerden F, Yonal-Hindilerden I, Akar E, et al. Severe Autoimmune Hemolytic Anemia in COVID-19 İnfection, Safely Treated with Steroids. Mediterr J Hematol Infect Dis. 2020;12(1):1-4
111. Pritchard M, Matthews N, Munro J. Antibodies to influenza A in a cluster of children with juvenile chronic arthritis. Br J Rheumatol. 1988;27(3):176–80.
dc.rights.none.fl_str_mv info:eu-repo/semantics/closedAccess
info:eu-repo/semantics/closedAccess
info:eu-repo/semantics/closedAccess
info:eu-repo/semantics/closedAccess
http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv closedAccess
rights_invalid_str_mv http://purl.org/coar/access_right/c_14cb
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Facultad de Ciencias para la Salud
Manizales
Especialización en Epidemiología
publisher.none.fl_str_mv Facultad de Ciencias para la Salud
Manizales
Especialización en Epidemiología
institution Universidad de Caldas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1836145034005577728
spelling Correlación entre las pruebas positivas de SARS-CoV-2 y el número de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila de marzo de 2020 a septiembre de 2021Análisis clínicosDiagnósticoNiñosInfecciones por coronavirusEnfermedades AutoinmunesNiñoPediatríaIlustraciones, mapas, gráficasspa: Introducción: Con el inició de la pandemia por COVID-19 se empezó a notar un aumento de casos reportados sobre manifestaciones autoinmunes en medio de la enfermedad y sobre casos nuevos de autoinmunidad tras la infección. Objetivo: Correlacionar la tasa de pruebas positivas de SARS-CoV-2 con la tasa de diagnósticos nuevos de enfermedad autoinmune en pacientes pediátricos del departamento del Huila, entre marzo de 2020 y septiembre de 2021. Métodos: Se realizó una caracterización sociodemográfica de los sujetos con diagnóstico de enfermedad autoinmune, una caracterización de los casos de SARS-CoV2, un análisis de la tendencia mensual de los casos de ambos eventos y finalmente, un modelo de correlación entre la tasa de diagnóstico de SARS-CoV2 y la tasa de enfermedades autoinmunes entre marzo de 2020 y septiembre de 2021. Resultados: Durante el periodo de estudio se diagnosticaron en Huila 94 casos de enfermedad autoinmune, con una edad promedio al diagnóstico de 8.3 años, la mayoría de sujetos fueron niñas y pertenecían a la zona urbana y al régimen de salud subsidiado, y la púrpura trombocitopénica inmune fue el diagnóstico más común. Se detectaron 4303 casos de SARS-CoV2, con una edad promedio de 7,9 años. Finalmente, se evidenció que la mayor tasa de enfermedad autoinmune se reportó justo después de los picos más altos de SARS-CoV2. Conclusiones: Este estudio no demostró una correlación estadística entre la tasa de pruebas positivas de SARS-CoV-2 y la tasa de diagnósticos nuevos de enfermedad autoinmune en los pacientes pediátricos del departamento durante los primeros dieciocho meses de la pandemia.eng: Introduction: With the onset of the COVID-19 pandemic, there was an increase in reported cases of autoimmune manifestations in the midst of the disease and new cases of autoimmunity after infection. Objective: To correlate the rate of positive tests for SARS-CoV-2 with the rate of new diagnoses of autoimmune disease in pediatric patients of the department of Huila, between March 2020 and September 2021. Methods: A socio-demographic characterization of the subjects diagnosed with autoimmune disease, a characterization of the cases of SARS-CoV2, an analysis of the monthly trend of the cases of both events and, finally, a correlation model between the rate of SARS-CoV2 diagnosis and the rate of autoimmune diseases between March 2020 and September 2021. Results: During the study period, 94 cases of autoimmune disease were diagnosed in Huila, with a mean age at diagnosis of 8. 3 years, most of the subjects were girls and belonged to the urban area and the subsidized health regime, and immune thrombocytopenic purpura was the most common diagnosis. A total of 4303 cases of SARS-CoV2 were detected, with a mean age of 7. 9 years. Finally, it was evidenced that the highest rate of autoimmune disease was reported just after the highest peaks of SARS-CoV2. Conclusions: This study did not show a statistical correlation between the rate of positive tests for SARS-CoV-2 and the rate of new diagnoses of autoimmune disease in pediatric patients of the department during the first eighteen months of the pandemic.Contenidos / Introducción / 2 Referente teórico/ 3 Objetivos / 4 Metodología / 5 Resultados /6 Discusión / 7 Conclusiones y recomendaciones / 10 Bibliografía.EspecializaciónEspecialista en EpidemiologíaFacultad de Ciencias para la SaludManizalesEspecialización en EpidemiologíaSepúlveda Gallego, Luz ElenaRestrepo Arias, Valeria Camila2022-10-06T17:23:21Z2022-10-06T17:23:21Z2022-10-06Trabajo de grado - Especializaciónhttp://purl.org/coar/resource_type/c_7a1fTextinfo:eu-repo/semantics/bachelorThesishttps://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85application/pdfapplication/pdfapplication/pdfapplication/pdfhttps://repositorio.ucaldas.edu.co/handle/ucaldas/18111Universidad de CaldasRepositorio Universidad de Caldashttps://repositorio.ucaldas.edu.co/mydspaceengspa1. Smatti M, Cyprian F, Nasrallah G, et al. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019 Aug 19;11(8):1-182. Richard-Eaglin A, Smallheer B. Immunosuppressive/Autoimmune Disorders. Nurs Clin North Am. 2018 Sep 1;53(3):319–34.3. V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020;19(3):155–70.4. Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clinical Immunology. 2020;217:1–2.5. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–206. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Current opinion in rheumatology. 2021;33(2):155–627. Gracia A, Martin E, Hernández G. New onset of autoimmune diseases following covid-19 diagnosis. Cells. 2021 Dec 1;10(12):1-198. Aggarwal A y Scott C. Global Issues in Pediatric Rheumatology. En Petty R, Laxer R, Lindsley C, et al. Textbook of Pediatric Rheumatology- ClinicalKey. 8th ed. Elsevier; 2020: 151-1569. Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Jt Bone Spine. 2014 Mar 1;81(2):112–710. CREA (Centro de estudios de Enfermedades Autoinmunes) [Sitio web de https://www.urosario.edu.co/]. 29 de enero de 2018. Disponible en: https://www.urosario.edu.co/Periodico-NovaEtVetera/Nuestra-U/El-5-de-la-poblacion-enColombia-sufre-de-alguna/. Consultado septiembre 12 de 2021.11. Palmezano J, Figueroa C, Rodríguez R, et al. Prevalencia y caracterización de las enfermedades autoinmunitarias en pacientes mayores de 13 años en un hospital de Colombia. Med interna México. 2018 J;34(4):522–35.12. Londoño J, Peláez I, Cuervo F, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD - Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Rev Colomb Reumatol. 2018;25(4):245–5613. Organización paramericana de la salud. Actualización Epidemiológica: Enfermedad por coronavirus (COVID-19) - [Sitio web de www.paho.org]. 21 de agosto de 2021. Disponible en: https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-porcoronavirus-covid-19-21-agosto-2021. Consultado en septiembre 11 de 2021].14. Gobernación del Huila - Emergencia por COVID 19. [Página web de www.huila.gov.co]. 2021. Disponible en: https://www.huila.gov.co/salud/publicaciones/9522/gobernacion-delhuila---emergencia-por-covid-19/. Consultado en junio 5 de 2021.15. Instituto nacional de salud. Modelos-covid-19 [Página web de www.ins.gov.co]. 2021 disponible en: https://www.ins.gov.co/Direcciones/ONS/modelos-covid-19. Consultado en septiembre 11 de 2021.16. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):276–8817. Iannarella R, Lattanzi C, Cannata G, et al. Coronavirus infections in children: From SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features. Acta Biomed. 2020;91(3):1–14.18. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatric Infectious Disease Journal. 2020 May;39(5):355-36819. Khera N, Santesmasses D, Kerepesi C, et al. COVID-19 mortality rate in children is Ushaped. Aging (Albany NY). 2021 Aug 8;13(16):54-62.20. Piedra L, Howe M, Francis J, et al. Latinos and the Pandemic: Results from the National Social Life, Health, and Aging Project—COVID-19 Study. J Appl Gerontol. 2022 May 1;41(5):1465-1472.21. Andrasfay T, Goldman N. Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations. medRxiv Prepr Serv Heal Sci. 2020 Oct 15; 118 (5): 1-2222. Thomas S, Griffiths C, Smeeth L, et al. Burden of Mortality Associated With Autoimmune Diseases Among Females in the United Kingdom. Am J Public Health. 2010 Nov 1;100(11):2279-2287.23. Mitratza M, Klijs B, Hak A, et al. Systemic autoimmune disease as a cause of death: mortality burden and comorbidities. Rheumatology (Oxford). 2021 Mar 1;60(3):1321–3024. Kim H, Cho S, Kim J, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 2020 Jun 1;50(3):526–33.25. Safiri S, Kolahi A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):1-1026. Barber M, Clarke A. Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017 Sep 1;29(5):480–527. Kent T, Davidson A, Newman D, et al. Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey. Lupus. 2017 Sep 1;26(10):1095–100.28. Jacobs P, Bissonnette R, Guenther L. Socioeconomic Burden of Immune-Mediated Inflammatory Diseases — Focusing on Work Productivity and Disability. J Rheumatol Suppl. 2011 Nov 1;88(88):55–61.29. Jiang M, Near A, Desta B, et al. Original research: Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015. Lupus Sci Med. 2021 Sep 14;8(1):1-1030. Strand V, Tundia N, Song Y, et al. Economic burden of patients with inadequate response to targeted immunomodulators for rheumatoid arthritis. J Manag Care Spec Pharm. 2018 Apr 1;24(4):344–52.31. Fair D, Rodriguez M, Knight A, et al. Depression And Anxiety In Patients With Juvenile Idiopathic Arthritis: Current Insights And Impact On Quality Of Life, A Systematic Review. Open Access Rheumatol Res Rev. 2019;11:237-252.32. Quilter M, Hiraki L, Korczak D. Depressive and anxiety symptom prevalence in childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2019 Jun 1;28(7):878–8733. Geist R, Grdisa V, Otley A. Psychosocial issues in the child with chronic conditions. Best Pract Res Clin Gastroenterol. 2003 Apr 1;17(2):141–52.34. Abdul-Sattar A, Magd S, Negm M. Associates of school impairment in Egyptian patients with juvenile idiopathic arthritis: Sharkia Governorate. Rheumatol Int. 2013 Sep 26;34(1):35– 42.35. Sentenac M, Santos T, Augustine L, et al. Chronic health conditions and school experience in school-aged children in 19 European countries. Eur Child Adolesc Psychiatry. 2022; 40(2):1-1136. Walsh S, Rau L. Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health. 2000;90(9):1463–6.37. Souza D, Santo A, Sato E. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol. 2012;39(3):496–503.38. Gacem O, Zeroual Z, Arrada Z, et al. Predictors of mortality in childhood-onset Systemic Lupus Erythematosus. Rheumatology. 2021 Nov 11;60(5):1–10.39. Yen E, McCurdy D. Autoimmune Diseases: Declining Mortality Between 1999 and 2008 However Continuing to be a Leading Cause of Death in Children-A 10-Year Retrospective Review. American College of Rheumatology. 2012;1–31.40. Jung S, Kim W. Targeted Immunotherapy for Autoimmune Disease. Immune Netw. 2022 Feb 1;22(1):1-2341. Departamento nacional de planeación. Ficha de caracterización 2019 [Página web de sirhuila.gov.co]. 30 de diciembre de 2019. Disponible en: http://tempo.sirhuila.gov.co/category/dnp/fichas-de-caracterizacion-municipal/. Citado el 12 de septiembre de 2021.42. Pollard C, Morran M, Kalinoski A. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52(11):549–57.43. Domingues R, Lippi A, Setz C, et al. SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime. Aging (Albany NY). 2020 Sep 30;12(18):18778–8944. Wang M, Zhao R, Gao L, et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020 Nov 25;10:1-17.45. Kutsuna S. Clinical Manifestations of Coronavirus Disease 2019. JMA J. 2021 Apr 4;4(2):76-80.46. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724.47. Dotan A, Muller S, Kanduc D, et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021 Apr 1;20(4):1–10.48. Chowdhury S, Oommen A. Epidemiology of COVID-19. J Dig Endosc. 2020;11(1):3-749. Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2021 Aug 31;1(9):1–9.50. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–4.51. Tang K, Hsu B, Chen D. Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review. Frontiers in Immunology. 2021;(12): 1-1652. Taherifard E, Movahed H. Hematologic autoimmune disorders in the course of COVID19: a systematic review of reported cases. Hematology. 2021;26(1):225–3953. Novelli L, Motta F, Santis M, et al. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmun. 2021;117(2021):1–24.54. Rodríguez Y, Novelli L, Rojas M, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020 Nov 1;114:1–1855. Li J, Liu H, Yin X, et al. COVID-19 illness and autoimmune diseases: recent insights. Inflamm Res. 2021;70(4):407–28.56. López M, Peral M, Calabuig I, et al. Case series of acute arthritis during COVID-19 admission. Ann Rheum Dis. 2021;80(4):1–2.57. Saricaoglu E, Hasanoglu I, Guner R. et al. The first reactive arthritis case associated with COVID‐19. J Med Virol. 2021;93(1):192–3.58. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):1–3.59. Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. 2020;383(3):1–260. Uppal N, Kello N, Shah H. et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int reports. 2020;5(11):1–5.61. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020 Jun 3;369:1–7.62. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1–8.63. Feldstein L, Rose E, Horwitz S, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. 2020;383(4):1–1364. Debliquis A, Harzallah I, Mootien J, et al. Haemophagocytosis in bone marrow aspirates in patients with COVID‐19. Br J Haematol. 2020;190(2):1–4.65. Wood H, Jones J, Hui K, et al. Secondary HLH is uncommon in severe COVID-19. Br J Haematol. 2020;190(5):1–3.66. M Verheyden, M Grosber, J Gutermuth. Et al. Relapsing symmetric livedo reticularis in a patient with COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(11):684–6.67. Dominguez M, Diaz B, Garcia P, et al. Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19). J Eur Acad Dermatol Venereol. 2020;34(10):536–7.68. Restivo D, Centonze D, Alesina A, et al. Myasthenia Gravis Associated With SARSCoV-2 Infection. Ann Intern Med. 2020;173(12):1–2.69. Foresti C, Servalli M, Frigeni B, et al. COVID-19 provoking Guillain-Barré syndrome: The Bergamo case series. Eur J Neurol. 2021 Oct;28(10):84-85.70. Mubarak M, Tolouian R, Kowalewska J, et al. Comment: Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis. 2020 jul 1;14(4):323–571. Slimani Y, Abbassi R, Zohra F. Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. J Med Virol. 2021;93(2):1184–7.72. Cardoso E, Hundal J, Feterman D, et al. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020;39(9):2811–5.73. Mehan W, Yoon B, Lang M. Paraspinal Myositis in Patients with COVID-19 Infection. AJNR Am J Neuroradiol. 2020 oct 1;41(10):1949–52.74. Riphagen S, Gomez X, Gonzalez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8.75. Saavedra C. Consenso Colombiano SARS-CoV-2/COVID-19. Infectio. 2021;25(4):153– 6776. Gobernación del Huila. Datos de primera infancia, infancia y adolescencia [Página web de huila.gov.co]. 12 de junio de 2020. Disponible en: 61 www.huila.gov.co/mujer/publicaciones/9578/datos-de-primera-infancia-infancia-yadolescencia/. Consultado en agosto 26 de 202177. Departamento Administrativo Nacional de Estadística (DANE). Censo nacional de población y vivienda 2018 [Página web de dane.gov.co]. 30 de agosto de 2019. Disponible en: https://sitios.dane.gov.co/cnpv/#!/est_pob. Consultado en: septiembre 8 de 202178. Instituto Nacional de Salud Colombia - Boletines casos COVID-19 Colombia [Página web de ins.gov.co]. 2021 disponible en: https://www.ins.gov.co/Paginas/Boletines-casosCOVID-19-Colombia.aspx. Consultado en: septiembre 28 de 202179. Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J Rheumatol. 1996 Nov; 23(11):1968–74.80. Rosenberg A. Longitudinal analysis of a pediatric rheumatology clinic population. J Rheumatol. 2005 Oct; 32(10):1992–2001.81. Terrell D, Beebe L, Vesely S, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010 Mar; 85(3):174–8082. Kamphuis S, Silverman E. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010 Sep; 6(9):538–46.83. Angum F, Khan T, Kaler J, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May;12(5):1-7.84. Sohn E. Why autoimmunity is most common in women. Nature. 2021 Jul 1;595(7867):51–3.85. Kühne T, Buchanan G, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003; 143(5):605–8.86. Instituto Nacional de Salud. El Coronavirus en Colombia [Página web de coronaviruscolombia.gov.co] 2022. Disponible en: https://coronaviruscolombia.gov.co/Covid19/index.html. Consultado el 30 de mayo de 2022.87. Wu Z, McGoogan J. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–42.88. Stokes E, Zambrano L, Anderson K, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. Morb Mortal Wkly Rep. 2020; 69(24): 759-765.89. American Academy of Pediatrics. Children and COVID-19: State-Level Data Report [Página web de www.aap.org]. 2022. Disponible en: https://www.aap.org/en/pages/2019- novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Consultado en: 30 de mayo de 2022.90. Dawood F, Porucznik C, Veguilla V, et al. Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. JAMA Pediatr. 2022 Jan 1; 176(1): 59–67.91. Dong Y, Mo X, Hu Y. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China - PMC. J Emerg Med. 2020 Apr;58(4):712–3.92. Murillo E, Aguilar F, Delgado I, et al. Predictors of laboratory-positive COVID-19 in children and teenagers. Public Health. 2020 Dec 1; 189 (2020):153-157.93. Wurzel D, McMinn A, Hoq M, et al. Original research: Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study. BMJ Open. 2021 Nov 8; 11(11):1-994. Pathak E, Salemi J, Sobers N, et al. COVID-19 in Children in the United States: Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020. J Public Heal Manag Pract. 2020 Apr 4; 26(4): 325–3395. Williams P, Howard A, Hsu P, et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020 Dec 1; 52(7):801.96. Chu V, Schwartz N, Donnelly M, et al. Comparison of Home Antigen Testing With RTPCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Intern Med. 2022 Apr 29; e221827: 1-997. Lindsay L, Secrest M, Rizzo S, et al. Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA. BMJ Open. 2021; 11:e051707: 1-1398. Lau C, Johns J, Merlene S, et al. Trends in COVID-19 Testing and Positivity Rates from a Mobile Testing Program in the Phoenix Metropolitan Area. J Community Health. 2021 Dec 1;46(6):1221–5.99. Naimoli A. Modelling the persistence of Covid-19 positivity rate in Italy. Socioecon Plann Sci. 2022 Jan 7;101225: 1-15100. Furuse Y, Ko Y, Ninomiya K, et al. Relationship of test positivity rates with covid‐19 epidemic dynamics. Int J Environ Res Public Health. 2021 Apr 27;18(9):1-10101. AlDallal A, AlDallal U, Al Dallal J. Positivity rate: an indicator for the spread of COVID19. Curr Med Res Opin. 2021;37(12):2067–76102. Lindsley C. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 1987;30(7):838–9.103. Feldman B, Birdi N, Boone J, et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996;129(4):513–8.104. Wong K, Farooq Alam Shah M, Khurshid M, et al. COVID-19 associated vasculitis: A systematic review of case reports and case series. Ann Med Surg. 2022 Feb 1;74:103249:1- 5105. Esposito S, Principi N. Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Paediatr Drugs. 2021;23(2):119-129.106. Talarico R, Stagnaro C, Ferro F, et al. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol. 2020;2(9):e518–9.107. Vacchi C, Meschiari M, Milic J, et al. COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. Rheumatology (Oxford). 2020;59(12):E147–50.108. Bonometti R, Sacchi M, Stobbione P, et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24(18):9695–7109. Bennett J, Brown C, Rouse M, et al. Immune Thrombocytopenia Purpura Secondary to COVID-19. Cureus. 2020 Jul; 12(7):1-5110. Hindilerden F, Yonal-Hindilerden I, Akar E, et al. Severe Autoimmune Hemolytic Anemia in COVID-19 İnfection, Safely Treated with Steroids. Mediterr J Hematol Infect Dis. 2020;12(1):1-4111. Pritchard M, Matthews N, Munro J. Antibodies to influenza A in a cluster of children with juvenile chronic arthritis. Br J Rheumatol. 1988;27(3):176–80.info:eu-repo/semantics/closedAccessinfo:eu-repo/semantics/closedAccessinfo:eu-repo/semantics/closedAccessinfo:eu-repo/semantics/closedAccesshttp://purl.org/coar/access_right/c_14cboai:repositorio.ucaldas.edu.co:ucaldas/181112024-07-16T21:42:06Z

Publicaciones similares